Climb Bio Set to Make Waves at Notable Investor Conferences
Climb Bio's Upcoming Investor Engagements
Climb Bio, Inc. (NASDAQ: CLYM), a pioneering clinical-stage biotechnology company focused on treatments for immune-mediated diseases, is gearing up for a series of significant investor conferences in September. These events provide an excellent platform for Climb Bio to showcase its innovative approach to therapeutic development and engage with the investment community.
Details on the Investor Conferences
During these conferences, members of Climb Bio's executive team will meet with stakeholders, presenting their latest research findings and therapeutic advancements. The following are the scheduled events:
Cantor Global Healthcare Conference
Format: Fireside chat and one-on-one investor meetings
Date: September 5, 2025 at 10:55 a.m. ET.
Baird Global Healthcare Conference
Format: Fireside chat and one-on-one investor meetings
Date: September 9, 2025 at 4:20 p.m. ET.
Morgan Stanley Annual Global Healthcare Conference
Format: One-on-one meetings only
Date: September 10, 2025.
Virtual Participation at Stifel Forum
Additionally, Climb Bio will participate in the Stifel Virtual Immunology and Inflammation Forum. This forum will consist of a presentation followed by individual meetings with investors, scheduled for September 10, 2025, at 10:30 a.m. ET. These interactions allow for enriching dialogue about Climb Bio's ongoing projects and future directions.
Accessible Webcasts and Replays
Investors interested in these events can access live webcasts via the "Investors and News" section of the Climb Bio website. Replays will be available approximately two hours after each event and will remain archived for at least 30 days, ensuring easy access to those unable to attend live.
About Climb Bio, Inc.
Climb Bio, Inc. is dedicated to transforming the treatment landscape for patients suffering from immune-mediated diseases. With a pipeline that features innovative therapeutics, such as budoprutug—an anti-CD19 monoclonal antibody—and CLYM116, an anti-APRIL monoclonal antibody, the company is poised for substantial growth. Budoprutug has shown promise in depleting B-cells, potentially addressing a range of B-cell mediated conditions. Meanwhile, CLYM116 is currently undergoing IND-enabling studies aimed at treating IgA nephropathy, highlighting Climb Bio's commitment to addressing unmet medical needs.
Contact Information for Investors
For investor inquiries, Climb Bio can be contacted through:
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
Frequently Asked Questions
What is Climb Bio known for?
Climb Bio specializes in developing therapeutics for immune-mediated diseases, focusing on innovative monoclonal antibodies.
When are Climb Bio's investor conferences?
They are set for September 5, 9, and 10 in 2025.
How can I access past conference webcasts?
Webcasts will be available on their website two hours after the events and archived for at least 30 days.
Who should I contact for investor information?
Contact Carlo Tanzi at Kendall Investor Relations via ctanzi@kendallir.com.
What is CLYM focusing on in its pipeline?
CLYM is developing treatments including budoprutug and CLYM116 to address B-cell mediated diseases.
About The Author
Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
